Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc > THE COMPANY COMPLETES ACQUISITION OF MAJOR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1219)
•••
Comment by CancerSlayeron Jan 01, 2021 7:31pm
242 Views
Post# 32208197

RE:THE COMPANY COMPLETES ACQUISITION OF MAJOR

RE:THE COMPANY COMPLETES ACQUISITION OF MAJORExpecting 2021 to be a big turning point for this company.  Psychedelics have already gotten the FDA nod when both Psilocybin & MDMA received breakthrough therapy status...both are in later-stage clinical trials for treatment-resistant depression & PTSD, respectively. Data dictates & it has been strongly positive.  Could be getting FDA approval for one or both by end of 2021 or 2022 imo.  Now just waiting for that first batch of proprietary Psilocybin.  If we can then prove low-cost production/scalability & integrate a library of psychoactive substances (not just Psilocybin) into the strip technology, it will be time to sing a new song, "Psychedelics in The Sky with Diamonds" : )
Keep it up Cool...

Wishing everyone a Happy & Prosperous New Year!  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities